Advertisement

Acute respiratory distress syndrome (ARDS) phenotyping

  • M. Shankar-Hari
  • E. Fan
  • N. D. Ferguson
Understanding the Disease

Clinically, the Berlin ARDS definition describes acute respiratory distress syndrome (ARDS) as acute hypoxaemic respiratory failure that is not fully explained by cardiac failure or fluid overload, that develops within 7 days of clinical recognition of a known risk factor, with bilateral radiographic opacities that are not fully explained by effusions, lobar/lung collapse, or nodules. Three risk strata were defined on the basis of the severity of hypoxaemia represented by the ratio of partial pressure of oxygen in arterial blood to inspired oxygen concentration (PaO2/FiO2 ratio), assessed at a minimum positive end-expiratory pressure (PEEP) of 5 cmH2O [1]. Hospital mortality worsens with severity of hypoxaemia and thus grade of ARDS (from 35% in mild ARDS to 46% in severe ARDS) [1, 2].

The ARDS consensus definitions to date have mainly relied on feasible clinical criteria, which helps to group patients together for inclusion in clinical trials and for clinical management [1, 3]. This...

Notes

Acknowledgements

This independent research by Dr Manu Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (NIHR-CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

Author contributions

Dr Shankar-Hari wrote the first draft of the manuscript. All authors contributed towards the critical revision of the manuscript for important intellectual content and confirm the integrity of the work.

Funding

Dr Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). Dr Fan is supported by a New Investigator Award from the Canadian Institutes of Health Research.

Compliance with ethical standards

Conflicts of interest

All authors declare that they do have any personal conflict of interest directly related to this manuscript.

References

  1. 1.
    ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526–2533Google Scholar
  2. 2.
    Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators, ESICM Trials Group (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:788–800CrossRefGoogle Scholar
  3. 3.
    Thompson BT, Chambers RC, Liu KD (2017) Acute respiratory distress syndrome. N Engl J Med 377:562–572CrossRefGoogle Scholar
  4. 4.
    Shankar-Hari M, Rubenfeld GD (2017) The use of enrichment to reduce statistically indeterminate or negative trials in critical care. Anaesthesia 72:560–565CrossRefGoogle Scholar
  5. 5.
    Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX (2016) Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194:147–155CrossRefGoogle Scholar
  6. 6.
    Fan E, Brodie D, Slutsky AS (2018) Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA 319:698–710CrossRefGoogle Scholar
  7. 7.
    Terpstra ML, Aman J, van Nieuw Amerongen GP, Groeneveld AB (2014) Plasma biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 42:691–700CrossRefGoogle Scholar
  8. 8.
    Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, NHLBI ARDS Network (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2:611–620CrossRefGoogle Scholar
  9. 9.
    Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS, ARDS Network (2017) Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195:331–338CrossRefGoogle Scholar
  10. 10.
    Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials Group (2018) Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6:691–698CrossRefGoogle Scholar
  11. 11.
    Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, ARDS Network (2018) Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax 73:439–445CrossRefGoogle Scholar
  12. 12.
    Sinha P, Delucchi KL, Thompson BT, McAuley DF, Matthay MA, Calfee CS, NHLBI ARDS Network(2018) Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study. Intensive Care Med 44:1859–1869CrossRefGoogle Scholar
  13. 13.
    Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, Artigas A, Martin-Loeches I, Hoogendijk AJ, van der Poll T, Horn J, Juffermans N, Calfee CS, Schultz MJ, MARS Consortium (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 72:876–883CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of Immunology and Microbial ScienceKings College LondonLondonUK
  2. 2.Guy’s and St Thomas’ NHS Foundation Trust, ICU Support OfficesSt Thomas’ HospitalLondonUK
  3. 3.Interdepartmental Division of Critical Care MedicineUniversity of TorontoTorontoCanada
  4. 4.University Health Network and Sinai Health SystemTorontoCanada

Personalised recommendations